BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McDonald LT. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol 2021;320:L257-65. [PMID: 33355522 DOI: 10.1152/ajplung.00238.2020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Bocchino M, Rea G, Buonocore A, Lieto R, Mazzocca A, Di Domenico A, Stanziola AA. Combination of acute exacerbation of idiopathic nonspecific interstitial pneumonia and pulmonary embolism after booster anti-COVID-19 vaccination. Respiratory Medicine Case Reports 2022;38:101674. [DOI: 10.1016/j.rmcr.2022.101674] [Reference Citation Analysis]
2 Hügle B, Krumrey-Langkammerer M, Haas JP. Infection with SARS-CoV-2 causes flares in patients with juvenile idiopathic arthritis in remission or inactive disease on medication. Pediatr Rheumatol Online J 2021;19:163. [PMID: 34844609 DOI: 10.1186/s12969-021-00653-8] [Reference Citation Analysis]
3 Bergantini L, Mainardi A, d’Alessandro M, Cameli P, Bennett D, Bargagli E, Sestini P. Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review. Front Pharmacol 2022;13:748931. [DOI: 10.3389/fphar.2022.748931] [Reference Citation Analysis]
4 Ntatsoulis K, Karampitsakos T, Tsitoura E, Stylianaki EA, Matralis AN, Tzouvelekis A, Antoniou K, Aidinis V. Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target. Front Immunol 2021;12:687397. [PMID: 34671341 DOI: 10.3389/fimmu.2021.687397] [Reference Citation Analysis]
5 Mohammadi A, Balan I, Yadav S, Matos WF, Kharawala A, Gaddam M, Sarabia N, Koneru SC, Suddapalli SK, Marzban S. Post-COVID-19 Pulmonary Fibrosis. Cureus 2022;14:e22770. [PMID: 35371880 DOI: 10.7759/cureus.22770] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 di Filippo L, Compagnone N, Frara S, Allora A, Doga M, Rovere Querini P, Cremona G, Giustina A. Vertebral fractures at hospitalization predict impaired respiratory function during follow-up of COVID-19 survivors. Endocrine 2022;77:392-400. [PMID: 35676466 DOI: 10.1007/s12020-022-03096-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Salem AM, Al Khathlan N, Alharbi AF, Alghamdi T, AlDuilej S, Alghamdi M, Alfudhaili M, Alsunni A, Yar T, Latif R, Rafique N, Al Asoom L, Sabit H. The Long-Term Impact of COVID-19 Pneumonia on the Pulmonary Function of Survivors. Int J Gen Med 2021;14:3271-80. [PMID: 34267545 DOI: 10.2147/IJGM.S319436] [Reference Citation Analysis]
8 Luger AK, Sonnweber T, Gruber L, Schwabl C, Cima K, Tymoszuk P, Gerstner AK, Pizzini A, Sahanic S, Boehm A, Coen M, Strolz CJ, Wöll E, Weiss G, Kirchmair R, Feuchtner GM, Prosch H, Tancevski I, Löffler-Ragg J, Widmann G. Chest CT of Lung Injury 1 Year after COVID-19 Pneumonia: The CovILD Study. Radiology 2022;:211670. [PMID: 35348379 DOI: 10.1148/radiol.211670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Gloeckl R, Leitl D, Jarosch I, Schneeberger T, Nell C, Stenzel N, Vogelmeier CF, Kenn K, Koczulla AR. Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Res 2021;7:00108-2021. [PMID: 34095290 DOI: 10.1183/23120541.00108-2021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
10 Martini K, Larici AR, Revel MP, Ghaye B, Sverzellati N, Parkar AP, Snoeckx A, Screaton N, Biederer J, Prosch H, Silva M, Brady A, Gleeson F, Frauenfelder T; European Society of Thoracic Imaging (ESTI), the European Society of Radiology (ESR). COVID-19 pneumonia imaging follow-up: when and how? A proposition from ESTI and ESR. Eur Radiol 2021. [PMID: 34713328 DOI: 10.1007/s00330-021-08317-7] [Reference Citation Analysis]
11 Prestes GDS, Simon CS, Walz R, Ritter C, Dal-pizzol F. Respiratory Outcomes After 6 Months of Hospital Discharge in Patients Affected by COVID-19: A Prospective Cohort. Front Med 2022;9:795074. [DOI: 10.3389/fmed.2022.795074] [Reference Citation Analysis]
12 Njoku IO, Aggarwal A, Bamgartner M, Lever JEP, Fleming TK. Letter regarding "Outcomes of a COVID-19 recovery program for patients hospitalized with SARS-CoV-2 infection in New York City: A prospective cohort study". PM R 2021;13:925-6. [PMID: 34143534 DOI: 10.1002/pmrj.12653] [Reference Citation Analysis]
13 Tiotiu A, Chong Neto H, Bikov A, Kowal K, Steiropoulos P, Labor M, Cherrez-Ojeda I, Badellino H, Emelyanov A, Garcia R, Guidos G. Impact of the COVID-19 pandemic on the management of chronic noninfectious respiratory diseases. Expert Rev Respir Med 2021;15:1035-48. [PMID: 34253132 DOI: 10.1080/17476348.2021.1951707] [Reference Citation Analysis]
14 Li R, Jia Y, Kong X, Nie Y, Deng Y, Liu Y. Novel drug delivery systems and disease models for pulmonary fibrosis. J Control Release 2022;348:95-114. [PMID: 35636615 DOI: 10.1016/j.jconrel.2022.05.039] [Reference Citation Analysis]
15 Di Ciaula A, Krawczyk M, Filipiak KJ, Geier A, Bonfrate L, Portincasa P. Noncommunicable diseases, climate change and iniquities: What COVID-19 has taught us about syndemic. Eur J Clin Invest 2021;51:e13682. [PMID: 34551123 DOI: 10.1111/eci.13682] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Li H, Hong X, Ding L, Meng S, Liao R, Jiang Z, Liu D. Sequence similarity of SARS-CoV-2 and humans: Implications for SARS-CoV-2 detection. Front Genet 2022;13:946359. [DOI: 10.3389/fgene.2022.946359] [Reference Citation Analysis]
17 Vianello A, Guarnieri G, Braccioni F, Lococo S, Molena B, Cecchetto A, Giraudo C, Bertagna De Marchi L, Caminati M, Senna G. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors. Clin Chem Lab Med 2021. [PMID: 34783228 DOI: 10.1515/cclm-2021-1021] [Reference Citation Analysis]
18 Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung Fibrosis after COVID-19: Treatment Prospects. Pharmaceuticals (Basel) 2021;14:807. [PMID: 34451904 DOI: 10.3390/ph14080807] [Reference Citation Analysis]
19 Thurzo A, Urbanová W, Waczulíková I, Kurilová V, Mriňáková B, Kosnáčová H, Gális B, Varga I, Matajs M, Novák B. Dental Care and Education Facing Highly Transmissible SARS-CoV-2 Variants: Prospective Biosafety Setting: Prospective, Single-Arm, Single-Center Study. IJERPH 2022;19:7693. [DOI: 10.3390/ijerph19137693] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Hamidi SH, Kadamboor Veethil S, Hamidi SH. Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective. Pharmacol Rep 2021;73:712-27. [PMID: 33880743 DOI: 10.1007/s43440-021-00255-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Leshchenko IV, Glushkova TV. Development of fibrosis and impairment of lung function in patients with a new coronavirus disease. Pulʹmonologiâ (Mosk ) 2021;31:653-62. [DOI: 10.18093/0869-0189-2021-31-5-653-662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Conte E. Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches. Pharmacol Ther 2021;:108031. [PMID: 34774879 DOI: 10.1016/j.pharmthera.2021.108031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Bai T, Zhou D, Yushanjiang F, Wang D, Zhang D, Liu X, Song J, Zhang J, Hou X, Ma Y. Alternation of the Autonomic Nervous System Is Associated With Pulmonary Sequelae in Patients With COVID-19 After Six Months of Discharge. Front Physiol 2022;12:805925. [DOI: 10.3389/fphys.2021.805925] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Giménez GC, Müller-Thies M, Prado FJ, Bach JR. Proposed Decannulation Criteria for COVID-19 Patients. Am J Phys Med Rehabil 2021;100:730-2. [PMID: 33990486 DOI: 10.1097/PHM.0000000000001788] [Reference Citation Analysis]
25 Achkar M, Jamal O, Chaaban T. Post-COVID lung disease(s). Ann Thorac Med 2022;17:137. [DOI: 10.4103/atm.atm_103_22] [Reference Citation Analysis]
26 Uchida N, Shimizu Y, Fujimaki M, Horibata Y, Nakamura Y, Horigane Y, Chibana K, Takemasa A, Sugimoto H, Niho S. Metabolic changes induced by TGF-β1 via reduced expression of phosphatidylserine decarboxylase during myofibroblast transition. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-121] [Reference Citation Analysis]
27 Doane JJ, Hirsch KS, Baldwin JO, Wurfel MM, Pipavath SN, West TE. Progressive Pulmonary Fibrosis After Non-Critical COVID-19: A Case Report. Am J Case Rep 2021;22:e933458. [PMID: 34848676 DOI: 10.12659/AJCR.933458] [Reference Citation Analysis]
28 Qin HC, He Z, Luo ZW, Zhu YL. Management of hip fracture in COVID-19 infected patients. World J Orthop 2022; 13(6): 544-554 [DOI: 10.5312/wjo.v13.i6.544] [Reference Citation Analysis]
29 Oatis D, Simon-Repolski E, Balta C, Mihu A, Pieretti G, Alfano R, Peluso L, Trotta MC, D'Amico M, Hermenean A. Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9. Int J Mol Sci 2022;23:8210. [PMID: 35897786 DOI: 10.3390/ijms23158210] [Reference Citation Analysis]
30 Jarosch I, Leitl D, Koczulla AR. [The pulmonary view on post-/Long-COVID]. Dtsch Med Wochenschr 2021;146:1559-63. [PMID: 34826844 DOI: 10.1055/a-1578-0347] [Reference Citation Analysis]
31 Borges U, Lobinger B, Javelle F, Watson M, Mosley E, Laborde S. Using Slow-Paced Breathing to Foster Endurance, Well-Being, and Sleep Quality in Athletes During the COVID-19 Pandemic. Front Psychol 2021;12:624655. [PMID: 34054642 DOI: 10.3389/fpsyg.2021.624655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Michalski JE, Kurche JS, Schwartz DA. From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic? Transl Res 2021:S1931-5244(21)00243-7. [PMID: 34547499 DOI: 10.1016/j.trsl.2021.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
33 Bocchino M, Lieto R, Romano F, Sica G, Bocchini G, Muto E, Capitelli L, Sequino D, Valente T, Fiorentino G, Rea G. Chest CT-based Assessment of 1-year Outcomes after Moderate COVID-19 Pneumonia. Radiology 2022;:220019. [PMID: 35536134 DOI: 10.1148/radiol.220019] [Reference Citation Analysis]
34 Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long-term complications of COVID-19. Am J Physiol Cell Physiol 2022;322:C1-C11. [PMID: 34817268 DOI: 10.1152/ajpcell.00375.2021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 27.0] [Reference Citation Analysis]
35 Okan S, Okan F, Duran Yücesoy F. Evaluation of pulmonary function and exercise capacity after COVID-19 pneumonia. Heart Lung 2022;54:1-6. [PMID: 35305515 DOI: 10.1016/j.hrtlng.2022.03.004] [Reference Citation Analysis]
36 Vaz de Paula CB, Nagashima S, Liberalesso V, Collete M, da Silva FPG, Oricil AGG, Barbosa GS, da Silva GVC, Wiedmer DB, da Silva Dezidério F, Noronha L. COVID-19: Immunohistochemical Analysis of TGF-β Signaling Pathways in Pulmonary Fibrosis. Int J Mol Sci 2021;23:168. [PMID: 35008594 DOI: 10.3390/ijms23010168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
37 King CS, Mannem H, Kukreja J, Aryal S, Tang D, Singer JP, Bharat A, Behr J, Nathan SD. Lung Transplantation of COVID-19 Patients: How I Do It. Chest 2021:S0012-3692(21)03668-0. [PMID: 34418410 DOI: 10.1016/j.chest.2021.08.041] [Reference Citation Analysis]
38 Nikitopoulou I, Fanidis D, Ntatsoulis K, Moulos P, Mpekoulis G, Evangelidou M, Vassiliou AG, Dimakopoulou V, Jahaj E, Tsipilis S, Orfanos SE, Dimopoulou I, Angelakis E, Akinosoglou K, Vassilaki N, Tzouvelekis A, Kotanidou A, Aidinis V. Increased Autotaxin Levels in Severe COVID-19, Correlating with IL-6 Levels, Endothelial Dysfunction Biomarkers, and Impaired Functions of Dendritic Cells. Int J Mol Sci 2021;22:10006. [PMID: 34576169 DOI: 10.3390/ijms221810006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Compagnone N, Palumbo D, Cremona G, Vitali G, De Lorenzo R, Calvi MR, Del Prete A, Baiardo Redaelli M, Calamarà S, Belletti A, Steidler S, Conte C, Zangrillo A, De Cobelli F, Rovere-Querini P, Monti G; COVID-BioB Study Group. Residual lung damage following ARDS in COVID-19 ICU survivors. Acta Anaesthesiol Scand 2022;66:223-31. [PMID: 34758108 DOI: 10.1111/aas.13996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
40 Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol 2021;12:698169. [PMID: 34248921 DOI: 10.3389/fmicb.2021.698169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
41 Singh A, Chakraborty S, Wong SW, Hefner NA, Stuart A, Qadir AS, Mukhopadhyay A, Bachmaier K, Shin JW, Rehman J, Malik AB. Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis. Proc Natl Acad Sci U S A 2022;119:e2121098119. [PMID: 35377803 DOI: 10.1073/pnas.2121098119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Castle RD, Williams MA, Bushell WC, Rindfleisch JA, Peterson CT, Marzolf J, Brouwer K, Mills PJ. Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation. J Inflamm Res 2021;14:4859-76. [PMID: 34588793 DOI: 10.2147/JIR.S323356] [Reference Citation Analysis]
43 Diaz H, Jiménez J, Hernández A, Valdés L, Martínez A, Porto L, Hernández R, Travieso N, Jova JH, Medel L, Troche M, Gorte A, Batista D, Valls AR, Cabrera L, Domeq M, Pérez L, Lorenzo-luaces P, Sánchez L, Saavedra D, Ramos M, Crombet T. Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario. Front Public Health 2022;10:948520. [DOI: 10.3389/fpubh.2022.948520] [Reference Citation Analysis]
44 Uemasu K, Yasuda Y, Hirayama Y, Arasawa S, Iwashima D, Takahashi KI. Post-COVID-19 interstitial lung disease presenting with profound hypoxemia: Report of three cases demonstrating a good response to high-dose corticosteroid therapy. J Infect Chemother 2021:S1341-321X(21)00321-4. [PMID: 34810106 DOI: 10.1016/j.jiac.2021.11.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Huang YY, Deng J, Tian YJ, Liang J, Xie X, Huang Y, Zhu J, Zhu Z, Zhou Q, He X, Luo HB. Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety. J Med Chem 2021;64:13736-51. [PMID: 34520193 DOI: 10.1021/acs.jmedchem.1c01085] [Reference Citation Analysis]
46 Giacomelli C, Piccarducci R, Marchetti L, Romei C, Martini C. Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients. Biochem Pharmacol 2021;193:114812. [PMID: 34687672 DOI: 10.1016/j.bcp.2021.114812] [Reference Citation Analysis]
47 Mattoo H, Pillai S. Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions. Cell Mol Life Sci 2021;78:5527-42. [PMID: 34145462 DOI: 10.1007/s00018-021-03874-y] [Reference Citation Analysis]
48 Myall KJ, Martinovic JL, West A. How COVID-19 interacts with interstitial lung disease. Breathe 2022;18:210158. [DOI: 10.1183/20734735.0158-2021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Binns C, Low WY. The Rich Get Richer and the Poor Get Poorer: The Inequality of COVID-19. Asia Pac J Public Health 2021;33:185-7. [PMID: 33759590 DOI: 10.1177/10105395211001662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Kahn AR, Schwalm CM, Wolfson JA, Levine JM, Johnston EE. COVID-19 in Children with Cancer. Curr Oncol Rep 2022. [PMID: 35113354 DOI: 10.1007/s11912-022-01207-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Ardahanli I, Akhan O, Sahin E, Akgun O, Gurbanov R. Myocardial performance index increases at long-term follow-up in patients with mild to moderate COVID-19. Echocardiography 2022. [PMID: 35294060 DOI: 10.1111/echo.15340] [Reference Citation Analysis]